Meta分析:炎症性肠病患者的乙型肝炎疫苗接种
该Meta分析纳入21项研究共2602例炎症性肠病患者,评估乙型肝炎疫苗应答率及预测因素。合并充分免疫应答率为62%(95%CI 55-68),有效免疫应答率为42%(95%CI 37-48)。标准剂量与双倍剂量、标准方案与加速方案间应答率相似,使用免疫调节剂(RR 0.73,95%CI 0.62-0.87)和抗TNF药物(RR 0.72,95%CI 0.60-0.87)为低应答预测因素。
要点
- 炎症性肠病患者乙肝疫苗合并充分免疫应答率62%,有效免疫应答率42%。
- 标准剂量与双倍剂量、标准方案与加速方案间应答率相似。
- 使用免疫调节剂或抗TNF药物者应答率降低,RR分别为0.73和0.72。
核心结论
- 炎症性肠病患者接种乙型肝炎疫苗后的血清学应答较差。
- 乙肝筛查和疫苗接种最好在开始使用免疫抑制药物之前完成。
研究设计与样本
- Meta分析,检索PubMed、Embase和Cochrane图书馆数据库。
- 纳入报告炎症性肠病患者乙肝疫苗应答的研究,共21项研究、2602例患者。
主要发现
- 乙肝疫苗接种后合并充分免疫应答(AIR,>10 IU/L)率为62%(95%CI 55-68)。
- 合并有效免疫应答(EIR,>100 IU/L)率为42%(95%CI 37-48)。
- 标准剂量与双倍剂量(10-20 μg或40 μg)的合并AIR和EIR率相似。
- 标准方案(0、1、6个月)与加速方案(0、1、2个月)的合并AIR和EIR率相当。
- 与未使用免疫抑制治疗相比,使用免疫调节剂(RR 0.73,95%CI 0.62-0.87)和抗TNF药物(RR 0.72,95%CI 0.60-0.87)是免疫应答不良的预测因素。
关键数值与推荐
- 充分免疫应答定义为>10 IU/L,有效免疫应答定义为>100 IU/L。
- 疫苗剂量分为10-20 μg和40 μg;方案分为标准方案(0、1、6个月)和加速方案(0、1、2个月)。
临床怎么用
- 作者认为,炎症性肠病患者乙肝筛查和疫苗接种最好在开始免疫抑制药物之前进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The response rate of hepatitis B virus (HBV) vaccination in patients with inflammatory bowel disease (IBD) is variable. Increasing dose or accelerated schedule is the suggested strategy to improve seroconversion. AIM: We performed a meta-analysis to determine the pooled response rate of HBV vaccination and to identify the predictors of seroconversion. METHODS: We searched PubMed, Embase and Cochrane library databases. Studies reporting the response of HBV vaccination in IBD patients were included. Response was recorded as adequate immune response (AIR, >10 IU/L) and Effective immune response (EIR, >100 IU/L). Pooled AIR and EIR rates were calculated for different doses (10-20 μg or 40 μg) and schedules (standard: 0, 1 and 6 months or accelerated: 0, 1 and 2 months). Meta-analysis was performed to identify the predictors of response. RESULTS: Twenty-one studies including 2602 patients were eligible. Pooled AIR and EIR rates after HBV vaccination were 62% (95% CI, 55-68) and 42% (95% CI, 37-48), respectively. Pooled AIR and EIR rates for standard and double dose were similar. Pooled AIR and EIR rates were also comparable for different schedules of HBV vaccination. Gender, IBD subtype and disease activity did not affect the response rate. Use of immunosuppression [immunomodulators (RR: 0.73, 95% CI, 0.62-0.87) and anti-TNFs (RR: 0.72, 95% CI, 0.60-0.87)] was a predictor of poor immune response compared to no immunosuppressive therapy. CONCLUSION: Patients with IBD have a poor serological response after HBV vaccination. HBV screening and vaccination should preferably be done before starting the immunosuppressive drugs.
引用
- Singh AK, Jena A, Mahajan G, et al. Meta-analysis: hepatitis B vaccination in inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35261057. doi:10.1111/apt.16880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。